title: Reply to G. Gandaglia et al and K. Lu.
authors.affiliation: University of Pennsylvania, Philadelphia, PA bekelman@uphs.upenn.edu.
authors.forename: Justin E
authors.initials: JE
authors.lastname: Bekelman
authors.affiliation: University of Pennsylvania, Philadelphia, PA.
authors.forename: Nandita
authors.initials: N
authors.lastname: Mitra
authors.affiliation: Fox Chase Cancer Center, Philadelphia, PA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Handorf
authors.affiliation: Fox Chase Cancer Center, Philadelphia, PA.
authors.forename: Robert G
authors.initials: RG
authors.lastname: Uzzo
authors.affiliation: MD Anderson Cancer Center, Houston, TX.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Hahn
authors.affiliation: University of Pennsylvania, Philadelphia, PA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Polsky
authors.affiliation: Massachusetts General Hospital, Boston, MA.
authors.forename: Katrina
authors.initials: K
authors.lastname: Armstrong
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal